Keywords: biolinerx, begins, new, bl-1020, study, israeli, drug
BioLineRx begins new BL-1020 study
Article | 21 May 2007
Israeli drug developer BioLineRx has initiated a study designed to determine the clinical binding properties of BL-1020, a developmental antipsychotic. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
